Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
Identifieur interne : 000674 ( Ncbi/Merge ); précédent : 000673; suivant : 000675Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
Auteurs : Michel St-Hilaire [Canada] ; Emmanuelle Bourhis ; Daniel Lévesque ; Claude RouillardSource :
- The European journal of neuroscience [ 0953-816X ] ; 2006.
English descriptors
- KwdEn :
- Adaptation, Physiological (drug effects), Adaptation, Physiological (genetics), Animals, Antiparkinson Agents (pharmacology), Benserazide (pharmacology), Corpus Striatum (drug effects), Corpus Striatum (metabolism), Corpus Striatum (physiopathology), DNA-Binding Proteins (genetics), Denervation, Disease Models, Animal, Dopamine (deficiency), Dopamine Agents, Drug Resistance (genetics), Enkephalins (genetics), Levodopa (pharmacology), Mice, Mice, Inbred C57BL, Mice, Knockout, Motor Activity (drug effects), Motor Activity (genetics), Neural Pathways (injuries), Neural Pathways (metabolism), Neural Pathways (physiopathology), Neurotensin (genetics), Nuclear Receptor Subfamily 4, Group A, Member 1, Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Receptors, Cytoplasmic and Nuclear (genetics), Receptors, Dopamine D3 (drug effects), Receptors, Dopamine D3 (metabolism), Receptors, Steroid (genetics), Transcription Factors (genetics).
- MESH :
- chemical , deficiency : Dopamine.
- chemical , drug effects : Receptors, Dopamine D3.
- chemical , genetics : DNA-Binding Proteins, Enkephalins, Neurotensin, Receptors, Cytoplasmic and Nuclear, Receptors, Steroid, Transcription Factors.
- chemical , metabolism : Receptors, Dopamine D3.
- chemical , pharmacology : Antiparkinson Agents, Benserazide, Levodopa.
- drug effects : Adaptation, Physiological, Corpus Striatum, Motor Activity.
- drug therapy : Parkinson Disease.
- genetics : Adaptation, Physiological, Drug Resistance, Motor Activity.
- injuries : Neural Pathways.
- metabolism : Corpus Striatum, Neural Pathways, Parkinson Disease.
- physiopathology : Corpus Striatum, Neural Pathways, Parkinson Disease.
- Animals, Denervation, Disease Models, Animal, Dopamine Agents, Mice, Mice, Inbred C57BL, Mice, Knockout, Nuclear Receptor Subfamily 4, Group A, Member 1.
Abstract
We have previously shown that dopamine (DA) denervation and repeated L-DOPA treatment modulate the pattern of Nur77 mRNA expression in the striatum. However, the exact role of this nuclear receptor in L-DOPA-induced molecular and behavioural adaptations observed in animal models of Parkinson's disease is still unknown. In the present study, we investigated the effects of Nur77 gene deletion on the development of behavioural sensitization and on changes in the regulation of neuropeptides and DA D(3) receptor expression following DA denervation and repeated L-DOPA treatment in Nur77+/+ and Nur77-/- hemiparkinsonian mice. One week postsurgery, hemiparkinsonian mice were treated with L-DOPA (10 mg/kg) plus benserazide (3 mg/kg) once a day for 7 days. Despite similar extents of nigrostriatal denervation, L-DOPA-induced rotational response was exacerbated in Nur77-/- mice compared to Nur77+/+ ones. However, the rate of increase of the rotational behaviour after repeated L-DOPA injections was similar in the two mouse strains. Lesioning the nigrostriatal pathway increased enkephalin (ENK) and neurotensin (NT) mRNA levels in both mouse strains. However, the up-regulation of these neuropeptides was significantly reduced in Nur77-/- mice. There was no difference in the modulation of D3 receptor density and dynorphin (DYN) mRNA expression between the two mouse strains. The present results suggest that Nur77 is involved in setting the threshold level for L-DOPA-induced rotational behaviour, rather than controlling the development of behavioural sensitization. This specific behavioural change is associated with a selective regulation of neuropeptide expression specifically in the indirect striatal output pathway.
DOI: 10.1111/j.1460-9568.2006.04954.x
PubMed: 16930409
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001153
- to stream PubMed, to step Curation: 001153
- to stream PubMed, to step Checkpoint: 001153
Links to Exploration step
pubmed:16930409Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.</title>
<author><name sortKey="St Hilaire, Michel" sort="St Hilaire, Michel" uniqKey="St Hilaire M" first="Michel" last="St-Hilaire">Michel St-Hilaire</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche en Neuroscience, CHUL, RC-9800, 2705 Boul. Laurier, Sainte-Foy, Québec, Canada G1V 4G2.</nlm:affiliation>
<country>Canada</country>
<wicri:regionArea>Centre de Recherche en Neuroscience, CHUL, RC-9800, 2705 Boul. Laurier, Sainte-Foy, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bourhis, Emmanuelle" sort="Bourhis, Emmanuelle" uniqKey="Bourhis E" first="Emmanuelle" last="Bourhis">Emmanuelle Bourhis</name>
</author>
<author><name sortKey="Levesque, Daniel" sort="Levesque, Daniel" uniqKey="Levesque D" first="Daniel" last="Lévesque">Daniel Lévesque</name>
</author>
<author><name sortKey="Rouillard, Claude" sort="Rouillard, Claude" uniqKey="Rouillard C" first="Claude" last="Rouillard">Claude Rouillard</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16930409</idno>
<idno type="pmid">16930409</idno>
<idno type="doi">10.1111/j.1460-9568.2006.04954.x</idno>
<idno type="wicri:Area/PubMed/Corpus">001153</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001153</idno>
<idno type="wicri:Area/PubMed/Curation">001153</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001153</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001153</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001153</idno>
<idno type="wicri:Area/Ncbi/Merge">000674</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.</title>
<author><name sortKey="St Hilaire, Michel" sort="St Hilaire, Michel" uniqKey="St Hilaire M" first="Michel" last="St-Hilaire">Michel St-Hilaire</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche en Neuroscience, CHUL, RC-9800, 2705 Boul. Laurier, Sainte-Foy, Québec, Canada G1V 4G2.</nlm:affiliation>
<country>Canada</country>
<wicri:regionArea>Centre de Recherche en Neuroscience, CHUL, RC-9800, 2705 Boul. Laurier, Sainte-Foy, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bourhis, Emmanuelle" sort="Bourhis, Emmanuelle" uniqKey="Bourhis E" first="Emmanuelle" last="Bourhis">Emmanuelle Bourhis</name>
</author>
<author><name sortKey="Levesque, Daniel" sort="Levesque, Daniel" uniqKey="Levesque D" first="Daniel" last="Lévesque">Daniel Lévesque</name>
</author>
<author><name sortKey="Rouillard, Claude" sort="Rouillard, Claude" uniqKey="Rouillard C" first="Claude" last="Rouillard">Claude Rouillard</name>
</author>
</analytic>
<series><title level="j">The European journal of neuroscience</title>
<idno type="ISSN">0953-816X</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation, Physiological (drug effects)</term>
<term>Adaptation, Physiological (genetics)</term>
<term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Benserazide (pharmacology)</term>
<term>Corpus Striatum (drug effects)</term>
<term>Corpus Striatum (metabolism)</term>
<term>Corpus Striatum (physiopathology)</term>
<term>DNA-Binding Proteins (genetics)</term>
<term>Denervation</term>
<term>Disease Models, Animal</term>
<term>Dopamine (deficiency)</term>
<term>Dopamine Agents</term>
<term>Drug Resistance (genetics)</term>
<term>Enkephalins (genetics)</term>
<term>Levodopa (pharmacology)</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Knockout</term>
<term>Motor Activity (drug effects)</term>
<term>Motor Activity (genetics)</term>
<term>Neural Pathways (injuries)</term>
<term>Neural Pathways (metabolism)</term>
<term>Neural Pathways (physiopathology)</term>
<term>Neurotensin (genetics)</term>
<term>Nuclear Receptor Subfamily 4, Group A, Member 1</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Receptors, Cytoplasmic and Nuclear (genetics)</term>
<term>Receptors, Dopamine D3 (drug effects)</term>
<term>Receptors, Dopamine D3 (metabolism)</term>
<term>Receptors, Steroid (genetics)</term>
<term>Transcription Factors (genetics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D3</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA-Binding Proteins</term>
<term>Enkephalins</term>
<term>Neurotensin</term>
<term>Receptors, Cytoplasmic and Nuclear</term>
<term>Receptors, Steroid</term>
<term>Transcription Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Dopamine D3</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benserazide</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Adaptation, Physiological</term>
<term>Corpus Striatum</term>
<term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adaptation, Physiological</term>
<term>Drug Resistance</term>
<term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="injuries" xml:lang="en"><term>Neural Pathways</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term>
<term>Neural Pathways</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term>
<term>Neural Pathways</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Denervation</term>
<term>Disease Models, Animal</term>
<term>Dopamine Agents</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Knockout</term>
<term>Nuclear Receptor Subfamily 4, Group A, Member 1</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have previously shown that dopamine (DA) denervation and repeated L-DOPA treatment modulate the pattern of Nur77 mRNA expression in the striatum. However, the exact role of this nuclear receptor in L-DOPA-induced molecular and behavioural adaptations observed in animal models of Parkinson's disease is still unknown. In the present study, we investigated the effects of Nur77 gene deletion on the development of behavioural sensitization and on changes in the regulation of neuropeptides and DA D(3) receptor expression following DA denervation and repeated L-DOPA treatment in Nur77+/+ and Nur77-/- hemiparkinsonian mice. One week postsurgery, hemiparkinsonian mice were treated with L-DOPA (10 mg/kg) plus benserazide (3 mg/kg) once a day for 7 days. Despite similar extents of nigrostriatal denervation, L-DOPA-induced rotational response was exacerbated in Nur77-/- mice compared to Nur77+/+ ones. However, the rate of increase of the rotational behaviour after repeated L-DOPA injections was similar in the two mouse strains. Lesioning the nigrostriatal pathway increased enkephalin (ENK) and neurotensin (NT) mRNA levels in both mouse strains. However, the up-regulation of these neuropeptides was significantly reduced in Nur77-/- mice. There was no difference in the modulation of D3 receptor density and dynorphin (DYN) mRNA expression between the two mouse strains. The present results suggest that Nur77 is involved in setting the threshold level for L-DOPA-induced rotational behaviour, rather than controlling the development of behavioural sensitization. This specific behavioural change is associated with a selective regulation of neuropeptide expression specifically in the indirect striatal output pathway.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16930409</PMID>
<DateCreated><Year>2006</Year>
<Month>08</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted><Year>2006</Year>
<Month>11</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0953-816X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>24</Volume>
<Issue>3</Issue>
<PubDate><Year>2006</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>The European journal of neuroscience</Title>
<ISOAbbreviation>Eur. J. Neurosci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.</ArticleTitle>
<Pagination><MedlinePgn>795-805</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We have previously shown that dopamine (DA) denervation and repeated L-DOPA treatment modulate the pattern of Nur77 mRNA expression in the striatum. However, the exact role of this nuclear receptor in L-DOPA-induced molecular and behavioural adaptations observed in animal models of Parkinson's disease is still unknown. In the present study, we investigated the effects of Nur77 gene deletion on the development of behavioural sensitization and on changes in the regulation of neuropeptides and DA D(3) receptor expression following DA denervation and repeated L-DOPA treatment in Nur77+/+ and Nur77-/- hemiparkinsonian mice. One week postsurgery, hemiparkinsonian mice were treated with L-DOPA (10 mg/kg) plus benserazide (3 mg/kg) once a day for 7 days. Despite similar extents of nigrostriatal denervation, L-DOPA-induced rotational response was exacerbated in Nur77-/- mice compared to Nur77+/+ ones. However, the rate of increase of the rotational behaviour after repeated L-DOPA injections was similar in the two mouse strains. Lesioning the nigrostriatal pathway increased enkephalin (ENK) and neurotensin (NT) mRNA levels in both mouse strains. However, the up-regulation of these neuropeptides was significantly reduced in Nur77-/- mice. There was no difference in the modulation of D3 receptor density and dynorphin (DYN) mRNA expression between the two mouse strains. The present results suggest that Nur77 is involved in setting the threshold level for L-DOPA-induced rotational behaviour, rather than controlling the development of behavioural sensitization. This specific behavioural change is associated with a selective regulation of neuropeptide expression specifically in the indirect striatal output pathway.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>St-Hilaire</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Centre de Recherche en Neuroscience, CHUL, RC-9800, 2705 Boul. Laurier, Sainte-Foy, Québec, Canada G1V 4G2.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bourhis</LastName>
<ForeName>Emmanuelle</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lévesque</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rouillard</LastName>
<ForeName>Claude</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Eur J Neurosci</MedlineTA>
<NlmUniqueID>8918110</NlmUniqueID>
<ISSNLinking>0953-816X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004745">Enkephalins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C539818">Nr4a1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057105">Nuclear Receptor Subfamily 4, Group A, Member 1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011987">Receptors, Steroid</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>39379-15-2</RegistryNumber>
<NameOfSubstance UI="D009496">Neurotensin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>762OS3ZEJU</RegistryNumber>
<NameOfSubstance UI="D001545">Benserazide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000222" MajorTopicYN="N">Adaptation, Physiological</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001545" MajorTopicYN="N">Benserazide</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003714" MajorTopicYN="N">Denervation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
<QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004745" MajorTopicYN="N">Enkephalins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName>
<QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009496" MajorTopicYN="N">Neurotensin</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057105" MajorTopicYN="N">Nuclear Receptor Subfamily 4, Group A, Member 1</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050637" MajorTopicYN="N">Receptors, Dopamine D3</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011987" MajorTopicYN="N">Receptors, Steroid</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>8</Month>
<Day>26</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>11</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>8</Month>
<Day>26</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16930409</ArticleId>
<ArticleId IdType="pii">EJN4954</ArticleId>
<ArticleId IdType="doi">10.1111/j.1460-9568.2006.04954.x</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><noCountry><name sortKey="Bourhis, Emmanuelle" sort="Bourhis, Emmanuelle" uniqKey="Bourhis E" first="Emmanuelle" last="Bourhis">Emmanuelle Bourhis</name>
<name sortKey="Levesque, Daniel" sort="Levesque, Daniel" uniqKey="Levesque D" first="Daniel" last="Lévesque">Daniel Lévesque</name>
<name sortKey="Rouillard, Claude" sort="Rouillard, Claude" uniqKey="Rouillard C" first="Claude" last="Rouillard">Claude Rouillard</name>
</noCountry>
<country name="Canada"><noRegion><name sortKey="St Hilaire, Michel" sort="St Hilaire, Michel" uniqKey="St Hilaire M" first="Michel" last="St-Hilaire">Michel St-Hilaire</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000674 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000674 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:16930409 |texte= Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16930409" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |